CN101947115A - Implantable human blood glucose concentration continuous monitoring system based on optical fiber attenuation total reflection - Google Patents
Implantable human blood glucose concentration continuous monitoring system based on optical fiber attenuation total reflection Download PDFInfo
- Publication number
- CN101947115A CN101947115A CN2010105067527A CN201010506752A CN101947115A CN 101947115 A CN101947115 A CN 101947115A CN 2010105067527 A CN2010105067527 A CN 2010105067527A CN 201010506752 A CN201010506752 A CN 201010506752A CN 101947115 A CN101947115 A CN 101947115A
- Authority
- CN
- China
- Prior art keywords
- optical fiber
- light
- path
- total reflection
- glucose concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention discloses an implantable human blood glucose concentration continuous monitoring system based on optical fiber attenuation total reflection, consisting of double optical paths and comprising a light source, an attenuator, a spectroscope, an optical fiber coupling device, an optical fiber ATR sensor, a measurement photodetector, a reference photodetector, a data collection system and a computer, wherein after being attenuated by the attenuator, the light source is divided into two optical paths formed by a measurement light and a reference light; in one optical path, the measurement light enters the optical fiber ATR sensor in a coupling way through a coupling method by the optical fiber coupling device and is received by the measurement photodetector via a transmission light of the optical fiber ATR sensor; in the other optical path, the reference light is directly received by the reference photodetector; signals recevied by the measurement photodetector and the reference photodetector are synchronously collected by the data collection system, are sent to the computer and are in analysis treatment, and the computer displays a measurement result and is also connected with the light source. The invention adopts a direct measurement in vivo method to directly measure the glucose concentration in a tissue fluid, thereby avoiding an error of measurement in vitro.
Description
Technical field
The present invention relates to a kind of human blood glucose concentration continuous monitoring device.Particularly relate to a kind of optical fiber ATR pick off that utilizes implant into body,, realize the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection of the continuous detecting of human blood glucose concentration by measuring the concentration of glucose in the subcutaneous tissue liquid.
Background technology
Diabetes are commonly encountered diseases and frequently-occurring diseases of middle-aged and elderly people, and sickness rate rises day by day, and are rejuvenation and extension trend.World health world organization classifies it and tumor, cardiovascular and cerebrovascular disease as three in the scope big difficult and complicated illness together.
Yet also do not have thoroughly to effect a radical cure at present the medical means of diabetes clinically, the target for the treatment of diabetes now is to realize insulin control as far as possible, avoids blood sugar for human body too high, prevents or alleviate the generation and the symptomatic treatment complication of complication.World health organisation recommendations is carried out the self-monitoring of blood glucose to diabetics, grasps intravital blood glucose situation at any time, realizes the accurate control to insulin, and this is significant for prevention and treatment diabetes and complication thereof.Therefore the accurate detection of human blood glucose concentration is the prerequisite and the basis of diabetes and complication prevention and treatment.
What present diabetes detected main dependence is to have wound to measure, and the blood sugar detecting method that extensively adopts all be unable to do without the blood process of getting that wound is arranged in the world.Having in the wound blood sugar test process needs consumable goods, and frequent blood sampling not only brings physiology and psychological pain to patient, the danger of wound infection in addition.Especially for clinical practice, the shortcoming of this method maximum is dynamic, the continuous detecting that can not realize for human blood glucose concentration, can't reflect the real-time change situation of blood sugar concentration in the patient body, does not therefore reach best clinical therapeutic efficacy.
Development along with laser and detection technique, various Woundless blood sugar detection methods based on optical technology, for example, utilize glucose molecule to the light transmission of near infrared light absorption characteristic and luminous reflectance spectrometry, Raman spectroscopy, polarimetry, optoacoustic method etc., and utilize glucose molecule to light polarization method of near infrared light polarization characteristic etc., become the popular research topic of Woundless blood sugar detection range.The Woundless blood sugar detection method does not need to extract substance in vivos such as blood, do not need pick off is implanted subcutaneous, the interaction of dependence light and human body specific part tissue detects the variation of blood sugar concentration in the patient body, can be dynamically, human body blood sugar concentration continuously, be optimal blood sugar for human body monitoring method.But the Woundless blood sugar detection technique is still immature, is in the experimentation stage can not be applied to clinically, can't satisfy dynamically, the requirement of human body blood sugar concentration continuously.And, so far still without any of the authentication of non-invasive blood-sugar detecting instrument device by U.S. FDA.
In view of many technical bottlenecks of shortcoming that the wound blood sugar test is arranged and Woundless blood sugar detection, the research of human blood glucose concentration continuous monitoring mainly concentrates on Wicresoft blood sugar test field in the world at present.Medical research shows that concentration of glucose and the concentration of glucose in the blood in the subcutaneous tissue liquid are closely-related.Therefore, can predict concentration of glucose in the blood by the concentration of glucose of monitoring in the tissue fluid.By detection mode, Wicresoft's blood sugar test technology can be divided into two big classes: a class is that the mode of tissue fluid with Wicresoft extracted from human body is subcutaneous, and then by stripped its concentration of glucose that detects of the method for electricity, optics or chemistry; Another kind of is microsensor directly to be implanted subcutaneous, detects concentration of glucose in the subcutaneous tissue liquid in real time at body.
Compare near infrared band, glucose has the unique absorption spectra that is called as " dactylogram " at middle infrared, and its absorption is much better than than near infrared band, and absworption peak is narrow.Therefore, mid infrared absorption spectrum comprises abundanter quantitative information, and extraction is easier, has more advantage when particularly detecting for the low content component.In infrared ATR absorption spectrometry overcome mid-infrared light in the transmission measurement method is used to absorb the penetration depth that causes limited because water is strong, only in 10 these inferior positions of the μ m left and right sides, receives much concern in the composition measurement field.
The ultimate principle of middle infrared attenuation full reflection absorption spectrometry is: under the condition of total reflection, light is decayed at crystal and sample contact surface.The degree of decay is relevant with the penetration depth of evanescent wave in sample, and penetration depth is by incident wavelength, angle of incidence, crystal and the decision of sample refractive index.It is this that the different characteristic of attenuation degree can be used to extract the information of component in the sample with the wavelength difference.Compare with traditional infrared transmission measurement, the key property of ATR method is: got rid of sample by the illumination post-heating and ruined may, sample thickness is not subjected to must be greater than the restriction of three times of optical wavelength.For optical fiber ATR probe designs, adopt working portion optical fiber circular, thereby in limited volumetric spaces, expand its effective active length, and its optical length can be developed according to demand around form, and then the detection resolution of raising optical fiber ATR pick off, to satisfy the demand of system optimal optical length.
1998, infrared ATR spectrographic method was used for the clinical chemistry analysis among the general such as Heise.The achievement in research that infrared ATR spectrographic method carried out the blood glucose continuous monitoring during Lambrecht equaled to deliver in 2006, the noise equivalent blood sugar concentration that isolated experiment obtains is 40mg/dL.Heise also begins concern mid-infrared light spectrometry blood sugar monitoring is used for Intensive Care Therapy in its article of delivering in 2008, adopts the microdialysis technology to extract subcutaneous tissue liquid, with the concentration of glucose in the mid-infrared light spectrometer research organization liquid.The shortcomings and deficiencies of wound blood sugar detecting method make this method of Heise finally also can't move towards clinical practice equally but tissue fluid extracting declines.
Summary of the invention
Technical problem to be solved by this invention is, provide a kind of employing in the body direct measuring method, directly measure the concentration of glucose in the tissue fluid, can satisfy in real time, the implanted human blood glucose concentration continuous monitor system that requires of blood sugar test continuously based on the optical fiber attenuation total reflection.
The technical solution adopted in the present invention is: a kind of implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection, constitute by double light path, include light source, attenuator, spectroscope, fiber coupling device, optical fiber ATR pick off, the measuring light detector, the reference light detector, data collecting system and computer, after described light source is decayed through attenuator, divide for two light paths that constitute by measuring light and reference light through spectroscope, a light path wherein is, described measuring light adopts fiber coupling device, be coupled into optical fiber ATR pick off by coupling process, through receiving by the measuring light detector of optical fiber ATR pick off through light; Another light path is that described reference light is directly received by the reference light detector; The described signal that is received through measuring light detector and reference light detector is sent to computer and is carried out analyzing and processing and show measurement result by the data collection system synchronizing collection, and described computer also is connected with light source.
Described light source is 1035 and the 1080cm that output wavelength comprises the glucose middle-infrared band
-1The miniaturization tunable wave length CO of characteristic absorption peak
2Laser instrument.
Described fiber coupling device three-dimensional is adjustable.
The fiber coupling device that described three-dimensional is adjustable includes: be respectively applied for fiber path and subcutaneous fiber path on the skin on the input path between fiber coupling device and the optical fiber ATR pick off, and fiber path and coupled two micro lens of subcutaneous fiber path on the skin on the emitting light path, the three dimension adjustable clamp that is used for fixing fiber path on two skins is held structure.
Described coupling process comprises the coupling process based on optical window or the saturating technology of optical clearing.
Described optical window comprises the cap-like structure that is used to protect the coupling port of fiber path and subcutaneous fiber path on the skin.
The saturating technology of described optical clearing is to smear the bio-compatible hypertonic preparation of setting concentration at skin surface, to strengthen the permeability of tissue to light.
Described optical fiber ATR pick off is to adopt monocycle or polycyclic sonde configuration to constitute by multimode fibre.
The optical fiber ATR gauge head of described optical fiber ATR pick off places in the miniature cavity, and the front end of described miniature cavity is for there being the semipermeable membrane with bio-compatibility of selecting trafficability characteristic to the molecule smaller or equal to glucose.
Be provided with the water-soluble polymer that glucose molecule is had specificity dynamic adsorption capacity and bio-compatibility in the described miniature cavity.
Implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection of the present invention adopts in the body direct measuring method, directly measures the concentration of glucose in the tissue fluid, has avoided stripped measurement error.Its advantage also is in bulk measurement, need not accurately to calculate the tissue fluid volume that extracts, and has further reduced the probability of introducing error.The implanted blood glucose continuous detecting technology based on the middle infrared optical fiber attenuated total reflectance that the present invention proposes can satisfy in real time, blood sugar test requirement continuously.
Have following characteristics:
1. ATR sensor probe of the present invention is made of optical fiber, and probe adopts annular design, has increased the active length of optical fiber ATR pick off in limited space.Sonde configuration is simple, and volume is little, easily makes, and can be implanted to the subcutaneous concentration of glucose that carries out of human body in body, continuous monitoring in 24 hours.
2. the present invention places miniature cavity with fibre-optical probe; the cavity front end is the semipermeable membrane with bio-compatibility, only allows micromolecule such as glucose can enter in the chamber, has avoided macromole to be adsorbed in optical fiber ATR sensor probe surface; play a protective role, prolonged the service life of probe.
3. utilization of the present invention has the water-soluble polymer of specificity dynamic adsorption capacity and bio-compatibility to glucose molecule, by its dynamic specific adsorption ability to glucose molecule, reduced the interference of other materials to measuring in the tissue fluid, realize the selective measurement of glucose molecule, improved Measurement Resolution.
4. patent of the present invention adopts bifocal path structure, comprises reference path and measures light path.The measurement error that the light source power fluctuation causes has been eliminated in the introducing of reference path, has improved the stability and the resolution of system.
5. the three-dimensional adjustable optic fibre coupling device of patent of the present invention makes optical fiber ATR pick off separate with the detection system of formations such as detector with light source, for clinical practice is laid a good foundation.
6. patent of the present invention proposes the coupling process based on the saturating technology of optical clearing, and optical fiber is imbedded in the subcutaneous 200 μ m, has reduced possibility of infection.
7. fibre-optical probe of the present invention, miniature cavity, semipermeable membrane and water-soluble polymer etc. are made by biocompatible material, and be safe and reliable, and human body is not had harm.
Description of drawings
Fig. 1 is an overall structure sketch map of the present invention;
Fig. 2 (a), Fig. 2 (b) are optical fiber ATR sonde configuration sketch maps of the present invention;
Fig. 3 is semipermeable membrane and the application sketch map of water-soluble polymer in middle infrared optical fiber ATR sensing probe;
Fig. 4 is that three-dimensional adjustable optic fibre coupling device makes optical fiber ATR pick off separate sketch map with detection system.
Fig. 5 is based on the system structure sketch map of optical window coupling process.
Fig. 6 is based on the system structure sketch map of the saturating coupling process of optical clearing.
Wherein,
1: light source 2: attenuator
3: spectroscope 4: fiber coupling device
5: optical fiber ATR pick off 6: measure the light path detector
7: reference path detector 8: data collecting system
9: computer 10: fiber path 1
11: monocycle ATR probe 12: fiber path 2
13: multi-ring ATR probe 14: polymer solution
15: organizer 16: biological semipermeable membrane
17: optical fiber 18: optical fiber ATR gauge head
19: subcutaneous fiber path 20: subcutaneous fiber path
21: cap-like structure 22: the optical fiber clamp structure
23: fiber path 24 on the skin: micro lens
25: fiber path 26 on the skin: skin
27: miniature cavity 28: glucose molecule
29: 30: the first labellings of polymer molecule
31: the second labellings
The specific embodiment
Below in conjunction with embodiment and accompanying drawing the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection of the present invention is made a detailed description.
As shown in Figure 1, implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection of the present invention, constitute by double light path, include light source 1, attenuator 2, spectroscope 3, fiber coupling device 4, optical fiber ATR pick off 5, measuring light detector 6, reference light detector 7, data collecting system 8 and computer 9.Wherein, after described light source 1 is decayed through attenuator 2, divide for two light paths that constitute by measuring light and reference light through spectroscope 3, a light path wherein is, described measuring light adopts fiber coupling device 4, be coupled into optical fiber ATR pick off 5 by coupling process, through being received by measuring light detector 6 through light of optical fiber ATR pick off 5, described coupling process comprises the coupling process based on optical window or the saturating technology of optical clearing; Another light path is that described reference light is directly received by reference light detector 7; The described signal that is received through measuring light detector 6 and reference light detector 7 is sent to computer 9 and is carried out analyzing and processing and show measurement result by data collecting system 8 synchronous acquisition, and described computer 9 also is connected with light source 1.The present invention utilizes the intravital optical fiber ATR of implant into body pick off, by measuring the concentration continuous monitoring of the concentration of glucose realization blood sugar for human body in the subcutis liquid.
Be that optical system structure of the present invention is a double light path, comprise reference path and measure light path.The detection signal of reference path detector and measurement light path detector carries out analyzing and processing and demonstration by the data collection system synchronizing collection by the program in the computer.The ratio of the reflected signal by two detected backgrounds of probe and testing sample according to the system linear characteristics, is converted into the trap of testing sample.The double light path design is that light source CO has been eliminated in the introducing of reference path
2The power swing of laser instrument has improved the stability and the resolution of system to the influence of measurement result.
Described light source 1 comprises 1035 and 1080cm of glucose middle-infrared band for output wavelength
-1Miniaturization tunable wave length CO Deng characteristic absorption peak
2Laser instrument, and its output wavelength spectral line line width help the detection and the extraction of signal.Described fiber coupling device 4 is three-dimensional adjustable fiber coupling devices.Attenuator 2 is adjustable continuously, and range of accommodation is 0.01%～100%, is lower than the human body safety criterion and satisfies the requirement that detector detects max power constraint with the power that guarantees incident optical ATR pick off.Measuring light detector 6 and reference light detector 7 are for being applicable to the pyroelectricity or the mercury cadmium telluride photodetector of middle-infrared band, the mercury cadmium telluride photodetector has liquid nitrogen refrigerating system, compare pyroelectric detector and can further improve Measurement Resolution, but the pyroelectric detector price is relatively cheap.
As shown in Figure 4, be divided into three parts: implant subcutaneous optical fiber ATR pick off 5, shown in the represented subcutaneous empty frame part of mark among Fig. 45 based on the implanted human blood glucose concentration continuous monitor system of optical fiber attenuation total reflection; Fiber coupling device 4 is shown in the 4 represented empty frame parts of mark among Fig. 4; The detection system that light source and detector etc. constitute.Thereby it is subcutaneous to make optical fiber ATR pick off implant, and outside the detection system of formations such as light source and detector is put, need not carry, for clinical practice is laid a good foundation.The fiber coupling device 4 that described three-dimensional is adjustable includes: be respectively applied for fiber path 25 and subcutaneous fiber path 19 on the skin on the input path between fiber coupling device 4 and the optical fiber ATR pick off 5, and fiber path 23 and subcutaneous fiber path 20 coupled two micro lens 24 on the skin on the emitting light path, the three dimension adjustable clamp that is used for fixing fiber path 25,23 on two skins is held structure 22.
As shown in Figure 5, based on the coupling technique of optical window, optical fiber is implanted subcutaneous, and coupling interface 19,20 and skin surface are flat.Scheme comprise be used to protect fiber path 25,23 on the skin and with the cap-like structure 21 of flat subcutaneous fiber path 19,20 coupling port of skin surface, be attached at skin surface at ordinary times, open during measurement.During the coupling process of optical window was used, the optical fiber coupling port was exposed skin surface, also increased possibility of infection when bringing inconvenience, but its coupling effect is better.
As shown in Figure 6, based on the system schematic of the saturating technology coupling process of optical clearing.Optical fiber coupling interface 19,20 is positioned in the subcutaneous 200 μ m, need be in order to the cap-like structure of protection optical fiber interface.Smear the bio-compatible hypertonic preparation of setting concentration (as glycerol in first, second mark 30,31 of skin surface of subcutaneous optical fiber correspondence, ethylene glycol etc., perhaps certain two kinds of mixing), after about 5 minutes, wipe the hypertonic preparation of skin surface, thereby eliminate the scattering process of skin surface direct reflection and subcutaneous composition, the pairing measuring point of subcutaneous optical fiber is strengthened the permeability of light, strengthen coupling effect.Positioner carries out optical fiber on the skin 25,23 to dock every skin according to predefined labelling with subcutaneous optical fiber 19,20.It is subcutaneous that the coupling process of the saturating technology of optical clearing is imbedded optical fiber, do not contact with the external world, reduced possibility of infection, but its coupling effect is general.
Shown in Fig. 2 (a), Fig. 2 (b), described optical fiber ATR pick off 5 is to adopt monocycle or polycyclic sonde configuration to constitute by multimode fibre, the annular design volume is little, satisfy pick off and implant subcutaneous requirement, in limited volumetric spaces, expand effective active length, improved the Measurement Resolution of optical fiber ATR pick off.The multimode fibre material is selected silver halide, and silver halide absorbs very little, flexible in middle-infrared band.The optimum pathway that can derive under the glucose absorption peak according to Lambert-Beer's law is long, can obtain higher sensitivity and less detection limit under the optimum pathway.Optimum pathway under single wavelength is by formula l
Optimal=1/ ∑ ε c decision, wherein ∑ ε c refers to that all substances are in extinction coefficient and its concentration sum of products of this wavelength in the solution.Linear type optical fiber total reflection number of times is limited, therefore the present invention adopts optical fiber by certain curvature bending, satisfying under the total reflection condition, increase the total reflection number of times, thereby reach the purpose that increases optical length, the loop configuration of optical fiber makes it obtain long active length in limited physical dimension, makes its implant into body become possibility.By adjusting the loop configuration of optical fiber ATR gauge head,, can obtain different optical lengths simultaneously as radius, annular number etc., long with the optimum pathway that satisfies system's detection needs, thus improve systematic survey sensitivity and precision.
As shown in Figure 3, the optical fiber ATR gauge head 18 of described optical fiber ATR pick off 5 places in the miniature cavity 27, and the front end of described miniature cavity 27 is for there being the semipermeable membrane with bio-compatibility 16 of selecting trafficability characteristic to the molecule smaller or equal to glucose.
Be provided with the water-soluble polymer that glucose molecule is had specificity dynamic adsorption capacity and bio-compatibility in the described miniature cavity 27.This polymer can adsorb glucose molecule, does not have effect for other molecule in the tissue fluid, has realized the selective measurement of glucose molecule, has strengthened spectral signal intensity simultaneously, has improved Measurement Resolution.
That is, the optical fiber ATR gauge head 18 of optical fiber ATR pick off 5 places miniature cavity, and the semipermeable membrane that the cavity port has bio-compatibility passes through the molecular selectivity smaller or equal to glucose, and protection optical fiber ATR probe is not adhered to by macromole, prolongs its service life.In addition, the mid-water-soluble polymer (* expression) that has pair glucose molecule to have dynamic selection absorbability and bio-compatibility of miniature cavity., weaken on the one hand and got rid of in the tissue fluid other material compositions the interference of glucose detection process has been realized that the selectivity of spectral information detects the absorption of the dynamic equilibrium formula of glucose molecule by water-soluble polymer; On the other hand because the absorption combination of glucose molecule and polymer molecule, polymer solution shown in mark 14 among Fig. 3, make that the attenuated total reflectance absorption spectrum signal that obtains when detecting glucose molecule has obtained strengthening and amplifying the resolution and the sensitivity that have improved spectral detection.
Implanted human blood glucose concentration continuous monitor system structure based on the optical fiber attenuation total reflection of the present invention adopts the double light path design, and measurement error and systematic survey principle that the fluctuation of double light path elimination light source power causes are as described below:
1, t
1Constantly, reference and the detected signal of measurement light path are as shown in Equation (1):
I
s=η
1T
bI
0Formula (1)
I
r＝η
2·I
0
Wherein, I
rAnd I
sBe respectively the detection signal of this reference constantly and measurement light path; η
1And η
2Be respectively the linear carry-over factor of measurement and reference path; I
0Be the laser instrument output intensity of this moment; T
bTransmitance for measuring samples at this moment.
2, t
2Constantly, reference and the detected signal of measurement light path are as shown in Equation (2):
I '
s=η
1T
sI '
0Formula (2)
I′
r＝η
2·I′
0
Wherein, I '
rAnd I '
sBe respectively the detection signal of this reference constantly and measurement light path; I '
0Be the laser instrument output intensity of this moment; T
sThe transmitance of measuring samples constantly for this reason.
Then two moment are determined by following formula by the change amount signal that the variation of measuring samples causes:
Parameter in right in the formula (3) is the parameter that can directly measure, and second of formula worked as laser instrument at t
1And t
2Output is identical constantly, both I '
0=I
0The time, its value is zero.Its implication is, if laser output power is stable, then measures the testing result of light path, and both first of formula (3) both had been actual value to be measured; If laser output power fluctuation, in the formula (3) second, both the measurement result of reference path was equivalent to the correction parameter of power swing, and the testing result in conjunction with the measurement light path can obtain actual value to be measured.Thereby the influence of the power swing of light source to measuring results eliminated in the introducing of reference path, improved the stability and the resolution of system.
The present invention is open and that disclose, and all combinations can produce by using for reference this paper disclosure, although combination of the present invention is described by detailed implementation process, but those skilled in the art obviously can be spliced change to device as herein described in not breaking away from content of the present invention, spirit and scope, or increase and decrease some parts.Specifically, the replacement that all are similar and change apparent to those skilled in the artly, they are regarded as being included among spirit of the present invention, scope and the content.
Claims (10)
1. implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection, it is characterized in that, constitute by double light path, include light source (1), attenuator (2), spectroscope (3), fiber coupling device (4), optical fiber ATR pick off (5), measuring light detector (6), reference light detector (7), data collecting system (8) and computer (9), it is characterized in that, after described light source (1) is decayed through attenuator (2), divide for two light paths that constitute by measuring light and reference light through spectroscope (3), a light path wherein is, described measuring light adopts fiber coupling device (4), be coupled into optical fiber ATR pick off (5) by coupling process, through receiving by measuring light detector (6) of optical fiber ATR pick off (5) through light; Another light path is that described reference light is directly received by reference light detector (7); The described signal that is received through measuring light detector (6) and reference light detector (7) is sent to computer (9) and is carried out analyzing and processing and show measurement result by data collecting system (8) synchronous acquisition, and described computer (9) also is connected with light source (1).
2. the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection according to claim 1 is characterized in that described light source (1) comprises 1035 and 1080cm of glucose middle-infrared band for output wavelength
-1The miniaturization tunable wave length CO of characteristic absorption peak
2Laser instrument.
3. the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection according to claim 1 is characterized in that, described fiber coupling device (4) is three-dimensional adjustable.
4. the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection according to claim 3, it is characterized in that, the fiber coupling device that described three-dimensional is adjustable (4) includes: be respectively applied for fiber path (25) and subcutaneous fiber path (19) on the skin on the input path between fiber coupling device (4) and the optical fiber ATR pick off (5), and fiber path (23) and coupled two micro lens of subcutaneous fiber path (20) (24) on the skin on the emitting light path, be used for fixing fiber path (25 on two skins, 23) three dimension adjustable clamp is held structure (22).
5. the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection according to claim 1 is characterized in that described coupling process comprises the coupling process based on optical window or the saturating technology of optical clearing.
6. the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection according to claim 5; it is characterized in that described optical window comprises the cap-like structure (21) of the coupling port that is used to protect fiber path on the skin (25,23) and subcutaneous fiber path (19,20).
7. the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection according to claim 5, it is characterized in that, the saturating technology of described optical clearing is to smear the bio-compatible hypertonic preparation of setting concentration at skin surface, to strengthen the permeability of tissue to light.
8. the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection according to claim 1 is characterized in that, described optical fiber ATR pick off (5) is to adopt monocycle or polycyclic sonde configuration to constitute by multimode fibre.
9. the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection according to claim 8, it is characterized in that, the optical fiber ATR gauge head (18) of described optical fiber ATR pick off (5) places in the miniature cavity (27), and the front end of described miniature cavity (27) is for there being the semipermeable membrane with bio-compatibility (16) of selecting trafficability characteristic to the molecule smaller or equal to glucose.
10. the implanted human blood glucose concentration continuous monitor system based on the optical fiber attenuation total reflection according to claim 9, it is characterized in that, be provided with the water-soluble polymer that glucose molecule is had specificity dynamic adsorption capacity and bio-compatibility in the described miniature cavity (27).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010506752.7A CN101947115B (en) | 2010-10-14 | 2010-10-14 | Implantable human blood glucose concentration continuous monitoring system based on optical fiber attenuation total reflection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010506752.7A CN101947115B (en) | 2010-10-14 | 2010-10-14 | Implantable human blood glucose concentration continuous monitoring system based on optical fiber attenuation total reflection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101947115A true CN101947115A (en) | 2011-01-19 |
| CN101947115B CN101947115B (en) | 2013-03-20 |
Family
ID=43450831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010506752.7A Expired - Fee Related CN101947115B (en) | 2010-10-14 | 2010-10-14 | Implantable human blood glucose concentration continuous monitoring system based on optical fiber attenuation total reflection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101947115B (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103637808A (en) * | 2013-11-18 | 2014-03-19 | 深圳先进技术研究院 | Photoacoustic imaging device |
| CN103917154A (en) * | 2011-09-06 | 2014-07-09 | 美敦力米尼梅德有限公司 | Orthogonally redundant sensor systems and methods |
| CN103919561A (en) * | 2014-03-25 | 2014-07-16 | 天津大学 | Flattened optical fiber ATR (attenuated total reflectance) glucose sensor reinforced on basis of metal nanoparticles |
| CN103919560A (en) * | 2014-03-25 | 2014-07-16 | 天津大学 | Bent optical fiber ATR (attenuated total reflectance) glucose sensor reinforced on basis of silver nanoparticles |
| CN104657576A (en) * | 2014-09-28 | 2015-05-27 | 东软熙康健康科技有限公司 | Blood glucose change presenting method and device |
| CN106037763A (en) * | 2016-07-04 | 2016-10-26 | 普乐药业有限公司 | Optical fiber sensor syringe |
| CN106483072A (en) * | 2015-08-28 | 2017-03-08 | 三星电子株式会社 | Optical pickocff and the method for operation optical pickocff |
| CN107072601A (en) * | 2014-06-03 | 2017-08-18 | 弗劳恩霍夫应用研究促进协会 | Glucose sensor |
| CN110269627A (en) * | 2019-08-02 | 2019-09-24 | 普乐药业有限公司 | Blood sugar measuring system and method |
| CN110811639A (en) * | 2019-11-06 | 2020-02-21 | 浙江清华柔性电子技术研究院 | Total bilirubin detection patch and total bilirubin detection system |
| WO2020152380A1 (en) | 2019-01-22 | 2020-07-30 | Universidad De Sevilla | Portable device and method for non-invasive blood glucose level estimation |
| CN111544011A (en) * | 2013-06-06 | 2020-08-18 | 普罗菲尤萨股份有限公司 | Apparatus and method for detecting optical signals from implanted sensors |
| JP2020185449A (en) * | 2013-03-14 | 2020-11-19 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ | Continuous glucose monitoring on-body sensor having visual display |
| US20200397362A1 (en) | 2019-06-20 | 2020-12-24 | International Business Machines Corporation | Lidar implantable biosensor for imaging biological tissue |
| CN113567387A (en) * | 2021-08-24 | 2021-10-29 | 广东得语健康科技有限公司 | Cavity-enhanced infrared absorption spectrum sugar urine detection system and detection method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6584335B1 (en) * | 1997-08-09 | 2003-06-24 | Roche Diagnostics Gmbh | Analytical device for in vivo analysis in the body of a patient |
| US20070010726A1 (en) * | 2002-10-02 | 2007-01-11 | Alfred E. Mann Inst. For Biomedical Engineering At The University Of Southern California | Internal biochemical sensing device |
| CN101548892A (en) * | 2009-04-29 | 2009-10-07 | 天津市先石光学技术有限公司 | Implanted in-vivo continuous blood sugar monitor |
| CN101819136A (en) * | 2010-04-23 | 2010-09-01 | 天津大学 | Human glucose concentration continuous monitoring device based on optical fiber surface plasmon resonance |
-
2010
- 2010-10-14 CN CN201010506752.7A patent/CN101947115B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6584335B1 (en) * | 1997-08-09 | 2003-06-24 | Roche Diagnostics Gmbh | Analytical device for in vivo analysis in the body of a patient |
| US20070010726A1 (en) * | 2002-10-02 | 2007-01-11 | Alfred E. Mann Inst. For Biomedical Engineering At The University Of Southern California | Internal biochemical sensing device |
| CN101548892A (en) * | 2009-04-29 | 2009-10-07 | 天津市先石光学技术有限公司 | Implanted in-vivo continuous blood sugar monitor |
| CN101819136A (en) * | 2010-04-23 | 2010-09-01 | 天津大学 | Human glucose concentration continuous monitoring device based on optical fiber surface plasmon resonance |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10194845B2 (en) | 2011-09-06 | 2019-02-05 | Medtronic Minimed, Inc. | Orthogonally redundant sensor systems and methods |
| CN103917154A (en) * | 2011-09-06 | 2014-07-09 | 美敦力米尼梅德有限公司 | Orthogonally redundant sensor systems and methods |
| US11229384B2 (en) | 2011-09-06 | 2022-01-25 | Medtronic Minimed, Inc. | Orthogonally redundant sensor systems and methods |
| CN103917154B (en) * | 2011-09-06 | 2016-01-27 | 美敦力米尼梅德有限公司 | Orthogonal redundancy sensing system and method |
| US11931145B2 (en) | 2011-09-06 | 2024-03-19 | Medtronic Minimed, Inc. | Orthogonally redundant sensor systems and methods |
| US9642568B2 (en) | 2011-09-06 | 2017-05-09 | Medtronic Minimed, Inc. | Orthogonally redundant sensor systems and methods |
| JP7164572B2 (en) | 2013-03-14 | 2022-11-01 | エンベクタ コーポレイション | Continuous glucose monitoring body-worn sensor with visual display |
| JP2020185449A (en) * | 2013-03-14 | 2020-11-19 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ | Continuous glucose monitoring on-body sensor having visual display |
| CN111544011A (en) * | 2013-06-06 | 2020-08-18 | 普罗菲尤萨股份有限公司 | Apparatus and method for detecting optical signals from implanted sensors |
| CN111544011B (en) * | 2013-06-06 | 2023-06-06 | 普罗菲尤萨股份有限公司 | Apparatus and method for detecting optical signals from implanted sensors |
| CN103637808B (en) * | 2013-11-18 | 2015-08-19 | 深圳先进技术研究院 | Opto-acoustic imaging devices |
| CN103637808A (en) * | 2013-11-18 | 2014-03-19 | 深圳先进技术研究院 | Photoacoustic imaging device |
| CN103919560A (en) * | 2014-03-25 | 2014-07-16 | 天津大学 | Bent optical fiber ATR (attenuated total reflectance) glucose sensor reinforced on basis of silver nanoparticles |
| CN103919561A (en) * | 2014-03-25 | 2014-07-16 | 天津大学 | Flattened optical fiber ATR (attenuated total reflectance) glucose sensor reinforced on basis of metal nanoparticles |
| CN107072601A (en) * | 2014-06-03 | 2017-08-18 | 弗劳恩霍夫应用研究促进协会 | Glucose sensor |
| CN107072601B (en) * | 2014-06-03 | 2021-10-26 | 弗劳恩霍夫应用研究促进协会 | Glucose sensor |
| CN104657576B (en) * | 2014-09-28 | 2017-09-22 | 东软熙康健康科技有限公司 | The rendering method and equipment of a kind of change of blood sugar |
| CN104657576A (en) * | 2014-09-28 | 2015-05-27 | 东软熙康健康科技有限公司 | Blood glucose change presenting method and device |
| CN106483072A (en) * | 2015-08-28 | 2017-03-08 | 三星电子株式会社 | Optical pickocff and the method for operation optical pickocff |
| CN106483072B (en) * | 2015-08-28 | 2020-12-29 | 三星电子株式会社 | Optical sensor and method of operating an optical sensor |
| CN106037763B (en) * | 2016-07-04 | 2019-01-25 | 普乐药业有限公司 | A kind of fibre optical sensor syringe |
| CN106037763A (en) * | 2016-07-04 | 2016-10-26 | 普乐药业有限公司 | Optical fiber sensor syringe |
| WO2020152380A1 (en) | 2019-01-22 | 2020-07-30 | Universidad De Sevilla | Portable device and method for non-invasive blood glucose level estimation |
| CN113795189A (en) * | 2019-06-20 | 2021-12-14 | 国际商业机器公司 | Lipid implantable biosensor for imaging biological tissue |
| WO2020254944A1 (en) * | 2019-06-20 | 2020-12-24 | International Business Machines Corporation | Lidar implantable biosensor for imaging biological tissue |
| GB2599329A (en) * | 2019-06-20 | 2022-03-30 | Ibm | Lidar implantable biosensor for imaging biological tissue |
| US20200397362A1 (en) | 2019-06-20 | 2020-12-24 | International Business Machines Corporation | Lidar implantable biosensor for imaging biological tissue |
| GB2599329B (en) * | 2019-06-20 | 2023-04-26 | Ibm | Lidar implantable biosensor for imaging biological tissue |
| US11864906B2 (en) | 2019-06-20 | 2024-01-09 | International Business Machines Corporation | LIDAR implantable biosensor for imaging biological tissue |
| CN110269627A (en) * | 2019-08-02 | 2019-09-24 | 普乐药业有限公司 | Blood sugar measuring system and method |
| CN110811639A (en) * | 2019-11-06 | 2020-02-21 | 浙江清华柔性电子技术研究院 | Total bilirubin detection patch and total bilirubin detection system |
| CN110811639B (en) * | 2019-11-06 | 2023-11-21 | 浙江清华柔性电子技术研究院 | Total bilirubin detection patch and total bilirubin detection system |
| CN113567387A (en) * | 2021-08-24 | 2021-10-29 | 广东得语健康科技有限公司 | Cavity-enhanced infrared absorption spectrum sugar urine detection system and detection method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101947115B (en) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947115B (en) | Implantable human blood glucose concentration continuous monitoring system based on optical fiber attenuation total reflection | |
| US6353226B1 (en) | Non-invasive sensor capable of determining optical parameters in a sample having multiple layers | |
| US5383452A (en) | Method, apparatus and procedure for non-invasive monitoring blood glucose by measuring the polarization ratio of blood luminescence | |
| CA2171640C (en) | Non-invasive blood analyte sensor | |
| US8452356B2 (en) | Optical microneedle-based spectrometer | |
| US5666956A (en) | Instrument and method for non-invasive monitoring of human tissue analyte by measuring the body's infrared radiation | |
| US6438397B1 (en) | Method and apparatus for analyte detection using intradermally implanted skin port | |
| CN101557752B (en) | Method for the glucose concentration in pulsational blood | |
| US7304724B2 (en) | Method and apparatus for quantification of optical properties of superficial volumes | |
| CN101194828B (en) | Nondestructive optics detecting device for Eye aqueous glucose concentration | |
| US8326390B2 (en) | Optical non-invasive blood monitoring system and method | |
| AU749033B2 (en) | Apparatus and method for noninvasive glucose measurement | |
| US20140330098A1 (en) | Reflectance calibration of fluorescence-based glucose measurements | |
| KR20150119855A (en) | Non-invasive blood analysis | |
| CA2380243A1 (en) | Optical sensor having a selectable sampling distance for determination of analytes | |
| CA2131715A1 (en) | Blood chemistry measurement by stimulated infrared emission | |
| CN115399759A (en) | Non-invasive blood analysis | |
| US20110118570A1 (en) | Optic sensor device with sers | |
| CN101264019A (en) | Novel portable non-invasive, continuous, real time blood sugar monitoring instrument based on light sound technique | |
| US7486976B1 (en) | Optical non-invasive blood monitoring system and method | |
| US8126527B2 (en) | Method and system for determining the contribution of hemoglobin and myoglobin to in vivo optical spectra | |
| Yamakoshi et al. | A new non-invasive method for measuring blood glucose using instantaneous differential near infrared spectrophotometry | |
| CN101435768B (en) | Apparatus and method for detecting specific substance concentration in solution by optical mode | |
| KR102348195B1 (en) | Optical Analyte Monitering System and Method | |
| Mignani et al. | Fibre-optic sensors in health care |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN XIANYANG SCIENCE AND TECHNOLOGY DEVELOPMEN Free format text: FORMER OWNER: XIANSHI OPTICAL TECHNOLOGY CO LTD, TIANJIN CITY |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20110402 Address after: 300072 Tianjin City, Nankai District Wei Jin Road No. 92 Applicant after: Tianjin University Co-applicant after: TIANJIN SUNRISE TECHNOLOGIES DEVELOPMENT Co.,Ltd. Address before: 300072 Tianjin City, Nankai District Wei Jin Road No. 92 Applicant before: Tianjin University Co-applicant before: Tianjin Sunshine Optics Technolies Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130320 Termination date: 20211014 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |